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Abstract 
Background: Multicriteria decision analysis (MCDA) has the potential to bring more structure and transparency to 
health technology assessment (HTA). The objective of this paper is to highlight key methodological and practical chal-
lenges facing the use of MCDA for HTA, with a particular focus on lower and middle-income countries (LMICs), and to 
highlight potential solutions to these challenges.
Methodological challenges: Key lessons from existing applications of MCDA to HTA are summarized, including: that 
the socio-technical design of the MCDA reflect the local decision problem; the criteria set properties of additive mod-
els are understood and applied; and the alternative approaches for estimating opportunity cost, and the challenges 
with these approaches are understood.
Practical challenges: Existing efforts to implement HTA in LMICs suggest a number of lessons that can help over-
come the practical challenges facing the implementation of MCDA in LMICs, including: adapting inputs from other 
settings and from expert opinion; investing in technical capacity; embedding the MCDA in the decision-making 
process; and ensuring that the MCDA design reflects local cultural and social factors.
Conclusion: MCDA has the potential to improve decision making in LMICs. For this potential to be achieved, it is 
important that the lessons from existing applications of MCDA are learned.
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Background
Health care decision making bodies across the world 
face the challenge of choosing which technologies to 
fund with scarce resources. his is supported by health 
technology assessment (HTA), to estimate the value for 
money of technologies. While factors other than cost 
and health beneit are acknowledged by HTA agencies 
[1], these are not always precisely measured, and their 
value is not formally assessed [2]. his has led to calls for 
methods capable of capturing the broader set of value 
of interest to payers, including consideration of, for 
instance, equity issues, burden of disease and a broader 
set of social beneits.
The past few years have witnessed a surge of interest 
in the use of multi-criteria decision analysis (MCDA) 
in HTA [3]. MCDA is a collection of approaches that 
support decision making by taking explicit account of 
multiple criteria. They guide decision makers through 
the process of agreeing what factors are relevant to a 
decision, measuring performance of options against 
these criteria, and understanding the trade-offs 
between values that may be conflicting. Without such 
structure, priority setting processes can be ad hoc, 
and not include all relevant stakeholders [2]. This is 
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particularly the case in lower and middle income coun-
tries (LMICs), where priority setting tends to be more 
complex due to there being limited evidence to inform 
decisions, countries’ fragile institutional capacity and 
the dominant influence of policy makers’ opinions and 
international donor agencies [4, 5]. In these circum-
stances, MCDA can support the quality of decision 
making and increase transparency and consistency [6].
A growing number of decision making bodies and 
HTA agencies in high income countries (HICs) are 
either using or starting to explore these approaches to 
improve their transparency and accountability, includ-
ing: Germany (Institute for Quality and Efficiency in 
Health Care [IQWiG]; [7] Italy (Lombardy); [8] South 
Korea; [9] Hungary; [10] UK (National Institute for 
Health and Care Excellence [NICE] highly specialised 
technology [11]). While a lot of attention is given to 
HIC’s use of MCDA, an unusually large proportion of 
published MCDAs for HTA are undertaken in LMICs. 
Two recent reviews of MCDAs in health care [3, 12] 
identified 10 studies of MCDAs used to inform HTA in 
LMICs, including: formulary management in Malaysia 
[13] and Cote d’Ivoire [14], and priority setting in Bra-
zil [15], Thailand [16, 17], Ghana [18, 19], Nepal [20], 
Morocco and Tunisia [21] and South Africa [22]. In 
one of these reviews, nine out of a total of 23 published 
MCDAs for HTA were undertaken in LMICs [3].
The objective of this paper is to provide an overview 
of the methodological and practical challenges facing 
the use of MCDA for HTA, with a particular focus on 
LMICs, and to highlight potential solutions to these 
challenges. The next section outlines methodological 
challenges facing the application of MCDA for HTA. 
The following section then considers some of the prac-
tical challenges to implementing MCDA, specific to 
LMICs. Four case studies of the application of MCDA 
in LMICs are referred to throughout these sections.
Methodological challenges
The use of MCDA for HTA is still in its infancy, and 
guidelines on good practice have only recently been 
published [24]. As guidelines are developed, it is 
becoming clear that many examples of MCDA for 
HTA, whether in LMICs or otherwise, are not applying 
good practice. It is important that those implementing 
MCDA in LMICs learn the lessons from this experi-
ence, and are aware of the current, more general meth-
odological debates in the application of MCDA for 
HTA. This section identifies some of these challenges 
and points towards good practice that can help practi-
tioners address them.
Positioning on the socio-technical continuum
Perhaps the irst challenge facing the design of an MCDA 
is to determine where on the socio-technical continuum 
the MCDA design should sit, ranging from purely delib-
erative to fully quantiied/algorithmic [25]. he techni-
cal element of MCDA addresses the analytical questions: 
how to ensure criteria properties and criteria set proper-
ties comply with good practice, how to measure perfor-
mance against these, how the criteria are weighted, and 
how performance and weights are aggregated. he social 
element of MCDA is concerned with which stakehold-
ers are involved in the MCDA, and when and how they 
contribute. here is no a priori optimal position on this 
spectrum. Technical and social elements need to work in 
concert to achieve the aims of the MCDA, and the appro-
priate combination of elements will depend on the deci-
sion problem.
It has been argued that HTA is an ethical problem, and 
that MCDA can support HTA by facilitating the delibera-
tion required for stakeholders with diverse perspectives 
to learn from one another and achieve agreement [26]. 
hat is, the appropriate MCDA design for HTA empha-
sises fair process, argumentation, iteration and system-
atic thinking, alongside the technicalities of preference 
elicitation and aggregation methods. However, whether 
this is the case will depend on the decision problem fac-
ing HTA agencies. For instance, the MCDA required by 
IQWiG to support economic evaluation would probably 
be considered towards the more technical end of the 
spectrum, involving the use of a discrete choice experi-
ment to elicit the preferences of large samples of patients 
[7].
he case studies highlighted in this paper illustrate a 
range of socio-technical approaches to MCDA for HTA. 
All involved signiicant stakeholder engagement in the 
design, implementation, and interpretation of the results 
of the MCDA. he stakeholders involved varied; for 
instance, criteria weights were elicited from policy mak-
ers in hailand (Table 1), Indonesia (Table 2) and Ghana 
(Table  3), but from the general population in Colombia 
(Table 4). In Ghana, Indonesia and hailand, the results 
of the MCDA were discussed and validated by decision 
makers before they used the MCDA to support their 
decision making. In Colombia, the MCDA had a more 
direct impact on decisions, with the technologies that 
performed best in the MCDA being included in beneits 
package until the point at which the available budget was 
spent.
It is recommended that those designing an MCDA 
are familiar with the decision problem, including the 
relevant stakeholders, and the alternative MCDA 
methods available to support this decision problem. 
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Decision makers should be engaged in deining the 
decision and the appropriate MCDA solution. Alterna-
tive approaches should be presented to decision mak-
ers, with an assessment of their relative merits, so that 
decision makers can input into the process of meth-
ods design. Regardless of where on the continuum the 
appropriate MCDA design is located, it is important to 
follow good practice recommendations relating to both 
the technical and social elements of MCDA [24, 27].
Quantifying the benefits of technologies
By far the most prevalent aggregation function adopted 
by MCDAs for HTA is the additive one. his has the 
advantage of being analytically simple. However, such 
simplicity requires that the criteria set have certain prop-
erties. In particular, they need to be non-overlapping (i.e., 
avoiding the double counting of the value generated by 
an alternative) and preferentially independent (i.e., the 
weight attached to one criterion should not depend on 
the performance on other criteria).
Table 1 Case study—Thailand [16, 23]
Thailand is a frontrunner in the use of MCDA to prioritise health interventions. Since 2009, the prioritisation of non-pharmaceutical products available 
under universal health coverage (UHC) has involved the following steps: (1) nomination of topics/interventions for assessment by seven groups of 
stakeholders, comprising policy makers, health professionals, civil society, academics, industries, general population and patient groups; (2) scoring of 
options against the selection criteria by the research team; (3) selection of topics/interventions for assessment by consultation panels of stakeholders 
representing the Thai health insurance system, policy makers and academics; (4) technology assessment of interventions by the research team; and 
(5) discussion of the assessment results and decision making by the SCBP. Final approval is sought from the subcommittee on health financing
The MCDA is embedded in a decision making institution, being initiated by the National Health Security Office (NHSO), the institute managing UHC. For 
instance, in 2009 the MCDA assessed 17 possible services for inclusion in UHC. The research team presented the results of the assessment of nine of 
these interventions to the SCBP, who recommended that three of these be considered for adoption under UHC
Table 2 Case study—Indonesia [29]
An MCDA was undertaken to inform the 5-year HIV/AIDs strategic plan in West Java province, Indonesia. Criteria and weights were agreed upon by a 
consultation panel, comprising 23 representatives from different government departments, community organisations, programme managers and 
researchers. A larger group of stakeholders proposed 50 interventions, which were scored by researchers. The consultation panel reflected on the 
results of the MCDA, incorporated other ethical considerations to prioritise investments and considered implementation, including who should fund 
and implement the prioritised interventions
The methods and results of the MCDA were included in West Java’s 5-year strategic document for HIV/AIDS control, which was approved by the gover-
nor in 2014. However, this was only a guidance document, and the extent to which it determines resource allocation is uncertain
Table 3 Case study—Ghana [18]
An MCDA was undertaken to guide the national Ministry of Health in Ghana in priority setting, by ranking 26 interventions. Specifically, the MCDA 
quantified the trade-off between equity, efficiency, and other societal concerns in health. A focus group of seven policymakers identified the relevant 
criteria for priority setting, including: the severity of the disease, the number of potential beneficiaries, the cost-effectiveness of the intervention, 
whether the intervention reduced poverty, and whether the intervention targeted a vulnerable population. A total of 63 policymakers participated in 
a discrete choice survey, and regression analysis was used to infer from their choices the weights associated with criteria
The priority-setting process was strongly embedded in the organisation context of the Ministry of Health to ensure its integration into the third Five 
Year Program of Work. Anecdotal evidence showed that policymakers used the study findings as part of the development of their Five Year Pro-
gramme of Work
Table 4 Case study—Colombia [38, 39]
With the cost of medications and devices seen as a threat to the sustainability of the funding of the health care system, between 2011 and 2013 the 
Instituto de Evaluación Tecnológica en Salud (IETS) implemented an MCDA to inform the inclusion of technologies in the health benefits package. 
The Ministry of Health undertook a systematic review to identify criteria, from which a shortlist was selected by relevant stakeholders. Technologies 
are scored against the criteria using 5-point Likert scales by stakeholders including Ministry of Health staff, citizens and physicians. Weights were 
obtained from a survey of 200 people from the Colombian general population
The MCDA informed the decision about additions to the health benefits package in 2013. Technologies that were candidates for inclusion but did not 
make it into the benefits package in 2011, as well as technologies that the judiciary had made available to individual patients, made up the list of 314 
technologies considered. The Ministry of Health prioritised 105 technologies for evaluation based on disease burden and the number of requests via 
tutela (the judicial mechanisms to request technologies not included in the benefits package). Based on the MCDA benefit-score and the available 
budget, 70 technologies were included in the benefits package
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Unfortunately, many applications of the additive model 
to HTA violate these requirements. Preferential depend-
ence—when the weight attached to one criterion is 
dependent on the performance on another—is a com-
mon problem in MCDAs for HTA. Perhaps the most 
prevalent example of this is the additive combination of 
health gain and severity of disease, when we might rea-
sonably expect the value of health gain to be dependent 
on disease severity [28]. hree of the four case studies 
presented in this paper are subject to this potential type 
of preferential dependence, including both severity of 
disease and efectiveness [hailand (Table  1), Colombia 
(Table 4)] or cost-efectiveness [Ghana (Table 3)]. In the 
presence of preferential dependence, the additive model 
is invalid and two options are available: adopt a diferent 
model structure that relects the non-additive relation-
ship between criteria, or update the criteria to ensure 
they are independent [24].
Measuring opportunity cost
HTA requires not only that the beneits of technologies 
are estimated, but also that opportunity cost is estimated 
using the same measure. his is the case whether HTA 
is supported by MCDA or other methods, such as cost-
efectiveness analysis. Where HTA involves a technol-
ogy-by-technology evaluation, we can distinguish three 
approaches to measure willing to pay (WTP) for gains 
measured on the MCDA-beneit scale. First, stated pref-
erence methods can be used to elicit stakeholders WTP 
for the beneits of technologies. Many MCDAs for HTA 
include cost or budget impact as a criterion. While not 
explicitly acknowledged by these studies, this is a stated 
preference approach. he weight elicitation stage of the 
MCDA essentially elicits stakeholder WTP for beneits. 
Two of the case studies presented in this paper include 
cost-efectiveness as a criterion [Ghana (Table  3) and 
Indonesia (Table 2)].
his approach, however, poses signiicant challenges. 
Oftentimes these MCDAs elicit weights separate from 
scales of performance. For instance, asking stakeholders 
to estimate the relative importance of ‘budget impact’ 
and ‘health gain’. However, without more precise deini-
tions of these criteria, including precise scale ranges, it 
is almost impossible to provide a precise WTP estimate. 
Even with more precise deinitions, it is questionable 
whether stakeholders would have the necessary knowl-
edge of the returns on current expenditure, or the cog-
nitive capacities to translate this into reliable responses 
to preference elicitation exercises. For instance, the rela-
tive weight attached to cost and beneits need to relect 
the willingness to pay for diferent beneits and how this 
changes in diferent circumstances. his challenge is 
exacerbated when the criterion is cost-efectiveness, as 
many diferent changes in efectiveness and cost could be 
relected in a single cost-efectiveness ratio.
hese concerns form the basis of the recommendation 
that MCDAs should not include cost or budget impact 
as a criterion, and instead that MCDA should be used to 
estimate the beneits of technologies. his is the approach 
adopted in the other two case studies [hailand (Table 1) 
and Colombia (Table  4)]. his broader beneit measure 
could then be compared against the incremental cost of 
the technology to form a new incremental cost-efec-
tiveness ratio (ICER). hen, akin to the current applica-
tion of the cost-efectiveness analysis, the eiciency of a 
technology is assessed by comparing an ICER against an 
opportunity cost threshold. he broader beneit measure 
could be seen as replacing the quality-adjusted life-year 
(QALY)—though the QALY could still be one of the cri-
teria making up this broader measure.
Two methods have been adopted to estimate such an 
opportunity cost threshold in the context of cost-efec-
tiveness analysis [30]. Both could be applied in the con-
text of MCDA, but doing so would pose challenges. First, 
an analysis of historic decisions to reveal decision mak-
ers’ preferences [31]. However, that no decisions would 
have been made using MCDA at the point of designing 
an HTA approach makes this unfeasible. Second, empiri-
cal estimates of the changes in beneits resulting from 
changes in expenditure [32]. his too faces practical 
challenges. Eforts to apply this approach to estimate the 
cost-efectiveness threshold have been criticised for the 
number of assumptions required to make up for the limi-
tations in the available data [33]. More challenges would 
be faced applying this approach to MCDA.
Faced with similar challenges when implementing cost-
efectiveness analysis, it has been proposed that LMICs 
adopt a strategy of extrapolating opportunity cost esti-
mates from wealthier settings [34] or estimating oppor-
tunity cost based on local income levels [35], especially in 
the absence of WHO guidance on the matter. he same 
approach cannot, however, be applied in the context of 
MCDA until these wealthier settings identify estimates of 
their own MCDA-based opportunity cost.
Alternatively, those designing HTA systems might 
avoid a technology-by-technology assessment process. If 
HTA involves the assessment of all technologies simulta-
neously, the challenge of estimating opportunity cost is 
removed. In that instance, a decision rule could take the 
form of investing in technologies in order of their ICERs 
until the budget is expended (see for instance Airoldi 
et al. 2011 [36]). In this instance, MCDA can be applied 
as part of programme budgeting marginal analysis [37]. 
his is the approach adopted in three of the four case 
studies presented in this paper—hailand (Table 1), Indo-
nesia (Table  2), and Ghana (Table  3). However, in none 
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of these instances was the whole health care budget or 
the whole beneits package considered, something which 
would be practically impossible. Instead, this application 
of MCDA is practically limited to individual care path-
ways or vertical programmes, such as HIV. As a conse-
quence, opportunity costs issue remains which are not 
considered by the analysis.
Practical challenges
Linked to the methodological challenges presented 
above, there are a number of practical challenges related 
to the application of MCDA as part of an HTA process. 
Many of these apply to HTA generally, whereas some are 
speciic to MCDA. Most are also more acute in resource 
constrained settings, whether in low income settings or 
middle income economies with budding HTA mecha-
nisms in the context of insurance agencies.
Informational requirements
Sourcing inputs in systems with less reliable informa-
tion systems, including limitations in context-speciic 
information, is a major challenge with HTA. Regardless 
of whether MCDA is employed, HTA will require data 
on (unit) costs, resource use, epidemiology, compara-
tive efectiveness speciic to the setting, and outcomes 
data including patient-reported outcomes. Distribution 
of health and access to health care is another type of 
information required by HTA, and while not speciic to 
LMICs, it is particularly important in LMICs.
he literature on the development of HTA systems in 
LMICs identiies potential solutions to gathering this 
data [40, 41]. Promising avenues for the collection of 
these data is collating and adapting evidence on efective-
ness from other settings; and the use of expert opinion to 
help translate evidence into the local setting and ill gaps 
in the evidence [42–44]. In the hai case study (Table 1) 
there was a lack of local scientiic information on one of 
the topic selection criteria ‘targeting the poor and those 
with rare diseases’. Performance against this criterion was 
determined on the basis of the hai experts’ opinion and 
international guidelines. hough caution is advised, as 
there are also examples of the application of external data 
to local settings that have not been successful, such as in 
the case of the Filipino health insurance scheme [45].
Faced with limited information, MCDA has a num-
ber of beneits. First, it is able to accommodate criteria 
deined and measured using expert opinion. Second, 
it allows for the formal consideration of the impact of 
uncertainty on the analysis. Relying on expert opinion, 
or generalising from evidence collected in other jurisdic-
tions, introduces uncertainty into HTA. By breaking up 
HTA into its components parts—criteria, performance 
and valuation—MCDA enables the impact of uncertainty 
in any of these components on the results of a HTA to 
be assessed [46]. his will allow a formal assessment of 
whether this uncertainty impacts on the conclusion of 
the MCDA.
MCDA also involves information requirements of its 
own, such as the need to attach appropriate weights/
scores relecting social preferences. Indeed, weight elici-
tation and how transparent and understandable those 
are to decision makers and the broader public is a gen-
eral practical challenge for MCDA. Some criteria used in 
MCDA, like equity, are di cult for non-experts to under-
stand. he elicitation of weights is a specialist activity, 
prone to bias, pointing to the need for appropriate tech-
nical capacity—the topic of the next section.
Technical capacity obstacles—different types of capacity 
shortfalls
Related to the informational/evidential challenges raised 
above, the relative lack of well-trained people who can 
initiate, manage and apply the whole process of HTA/
MCDA is a practical obstacle to its routine introduction, 
especially in LMIC settings. Technical capacity required 
to deliver an MCDA includes: knowledge of good MCDA 
practice, such as the properties of criteria required to 
implement an additive model (see above); modelling 
skills, though most MCDA models are not technically 
demanding; and preference elicitation expertise. he lat-
ter may include techniques such as decision conferenc-
ing, which encourage stakeholders to express their views, 
facilitate the generation of consensus and help inform the 
model as it develops on-the-spot with continuous display 
of the model’s results through a highly ‘interactive and 
iterative group process’ [47].
he ability to commission and quality assure MCDAs 
from the right groups on behalf of decision makers, and 
of translating the indings into policy language and spe-
ciic and actionable recommendations, is an important 
one which is often lacking in LMICs. his said, there are 
examples of countries that within a 5- to 10-year period 
have built a signiicant capacity, technical, clinical, politi-
cal and administrative, in support of HTA including 
MCDA, such as hailand with the Health Intervention 
and Technology Assessment Program (HITAP) [16, 23, 
48, 49]. Also, regional initiatives such as HTAsiaLink can 
help countries work together, oftentimes pooling experi-
ences as well as expertise, to support local decision mak-
ing eforts [41, 50]. Finally, while training programmes at 
local universities are often in short supply, they are avail-
able. Mahidol’s HTA postgraduate programmes in South-
east Asia is one such example [51]. Its programmes were 
established in 2016, partly with funding from iDSI [52], 
to build up social and intellectual capital for, ultimately, 
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strengthening and sustaining capacity for HTA research 
and implementation, and support UHC in LMICs.
Issues of governance, institutions and consistency 
in decision making
he MCDA literature tends to emphasise the technical 
aspects of implementation, such as those describe above. 
Relatively little attention is paid to the extent to which the 
MCDA is embedded in the institutional policy-making 
process, something that is necessary to ensure that its 
results will actually be used [29]. Five of the nine exam-
ples of MCDAs for HTA in LMICs identiied by Marsh 
et  al. [3] were applied in an institutional setting; three 
being used to support decisions [16, 18, 22] and two 
being exploratory studies involving oicials [14, 17].
he embedding of MCDA in relevant decision-making 
processes requires established or mature enough institu-
tions. First, if such institutions do not exist, the ability 
to engage relevant stakeholders to elicit their input into 
the implementation of the MCDA, as well as to commu-
nicate the results of the MCDA, can be undermined by 
limited trust in public institutions. Second, institutions 
are required that are able to carry out or at least inlu-
ence budgetary allocation (or de-allocation). Obstacles to 
implementing decisions include: weak regulation; unre-
liable payment mechanisms; or misaligned ones such as 
‘Fee For Service’ which can encourage supply-induced 
demand, and a lack of efective performance-based con-
tracts. Additional practical challenges include the frag-
mentation of decision making structures and of inancing 
cash lows, including oftentimes between central and fed-
eral or public and private sectors, and between decision 
makers at the Ministry of Health and various insurance 
schemes as well as signiicant out of pocket spending.
However, where policy makers develop an interest in 
HTA, there are signiicant opportunities for progress in 
terms of institutionalising HTA-type approaches. his 
can be facilitated by creating positions within ministries 
and insurance funds for supporting institutions, and sig-
nalling to academic institutions, the health care products’ 
industry and international players that the government 
is determined to adopt a more explicit and evidence 
informed approach to priority setting. India, through the 
Indian Council of Medical Research and the Department 
for Health Research at the Union level, and China, under 
the leadership of the National Health and Family Plan-
ning Commission, both recently announced the launch of 
HTA institutions and networks, respectively, to support 
the transition to UHC [53–55]. Another encouraging 
experience can be found in hailand. he hai experi-
ence highlights the need for senior igures from pow-
erful bodies to champion MCDA. he introduction of 
MCDA/HTA in hailand was supported by the chair of 
the sub-committee of UHC beneit package development 
and the chair of the committee of National List of Essen-
tial Medicines, both of whom realised the importance of 
evidence-informed decision making [16, 48, 56].
he role of international donors in LMICs creates both 
challenges to and opportunities for the embedding of 
MCDA in decision making. To the extent to which donors 
use MCDA to support their own decision making, their 
demands for related evidence can drive the adoption of 
MCDA in LMICs. Further, donors or funding conduits 
such as the Global Fund [57], can contribute to the build-
ing of in-country capacity, technical and institutional, for 
commissioning, carrying out and applying MCDAs to 
decisions about countries’ own spending, which is increas-
ingly important as countries transition away from aid. he 
potential for applying MCDA in the context of speciic 
diseases and conditions, with its structured approach to 
stakeholder engagement and explicitness about considera-
tion of issues such as equity and human rights, ought to 
make its application attractive to funding channels such as 
Gavi, which funds vaccines, and the Global Fund, which is 
responsible for funding interventions targeting HIV/AIDS, 
TB and malaria in developing countries.
On the other hand, donor’s inluence may have a detri-
mental impact on the adoption of MCDA. Being explicit 
about opportunity costs or costs in general can often seem 
controversial in the global development world, acknowl-
edging budgetary constraints is often deemed unethical 
and economists demonised [58, 59]. Further, when funding 
pots are limited to vaccines or a certain disease such as TB 
or HIV, issues of allocative eiciency become less relevant 
in the short term, at least for the foreign budget holders 
making investment choices in poorer countries. We hope 
however, that as the value for money rhetoric [60] inds its 
way into government policies in rich and poorer countries, 
MCDA will ofer a means for considering in a systematic 
fashion most of the things that matter when allocation 
decisions are made, including costs and distribution.
Cultural and social factors
MCDA presents the possibility of formally and transpar-
ently incorporating local cultural and social factors into 
decision making. It is not only the health and economic 
impacts of interventions that are of interest in HTA, but 
also the social, ethical, and institutional implications of a 
technology. MCDA can help HTA consider these factors, 
by incorporating them into the criteria list and weight-
ing them to relect their relative importance to stake-
holders. For instance, the example of the use of MCDA 
to inform UHC in hailand demonstrates the inluence 
of social values throughout the MCDA, from the topic 
selection stage, through the inclusion of health tech-
nologies that are not equally accessible throughout the 
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country or across diferent health facilities, to the criteria 
relecting equity and social implications, with preference 
given to health problems inlicting the poor or minority 
groups with rare diseases [16]. Another example is the 
Indonesian case study (Table 2), which includes a crite-
rion measuring the impact of interventions on the stigma 
associated with being HIV positive.
Furthermore, by structuring stakeholder input, and by 
explicitly incorporating cultural and social factors into 
decision criteria, MCDA reduces the risk that decision 
making is unduly inluenced by local power structures. 
However, adopting MCDA does not guarantee stake-
holders’ representation in decision making. In LMICS, 
the technical nature of MCDA may result in deliberations 
being dominated by highly educated people with the 
views of the majority less well relected [61]. It is impor-
tant that this is considered when designing the MCDA 
process, so that the appropriate support is provided to 
allow everyone to participate.
Conclusion
MCDA is increasingly being considered as a means 
to address some of the limitations with existing HTA 
methods. In particular, MCDA ofers a means to more 
formally and transparently capture the multiple factors 
relevant to HTA. Despite the attention given to debates 
in high income countries, an unusually large proportion 
of published MCDAs for HTA are undertaken in LMICs. 
his may be explained by the lack of established HTA 
methodologies in LMICs, allowing recent innovations to 
take hold. his literature, and broader debates about the 
application of MCDA in health care, point to a number of 
lessons for those implementing MCDA in LMICs:
1. It is important that new eforts to implement MCDA 
in LMICs don’t replicate the technical limitations of 
existing applications, such as ignoring the preferen-
tial dependence between criteria (e.g. severity of dis-
ease and health gain). hose implementing MCDAs 
should familiarize themselves with recent good prac-
tice guidance.
2. he estimation of opportunity cost for use in an 
MCDA-framework that undertakes technology-by-
technology evaluations is a signiicant challenge. his 
can be somewhat addressed if the decision prob-
lem can be deined to be prioritizing which of many 
interventions to fund from a ixed budget.
3. A lack of evidence in LMICs can partly be addressed 
through generalizing from evidence generated in 
other settings and the use of expert opinion, in com-
bination with an analysis of the impact of uncertainty 
on the conclusions of the MCDA.
4. Investment in technical capacity is necessary to 
ensure a rigorous implementation of the MCDA, in 
particular the design of the overall MCDA approach, 
and the elicitation of weights.
5. If it is to impact decision making, it is important that 
the design of the MCDA relects the local decision 
problem, including being embedded in decision mak-
ing institutions, and engaging relevant stakeholders 
in design, implementation, and interpretation.
Abbreviations
CUA : cost-utility analysis; DSU: Decision Support Unit; HIC: high income 
country; HITAP: Health Intervention and Technology Assessment Program; 
HTA: health technology assessment; ICER: incremental cost-effectiveness 
ratio; IETS: Instituto de Evaluación Tecnológica en Salud; IQWiG: Institute for 
Quality and Efficiency in Health Care; LMIC: lower and middle income country; 
MCDA: multi-criteria decision analysis; NHSO: National Health Security Office’s; 
NICE: National Institute for Health and Care Excellence; QALY: quality-adjusted 
life-year; SCBP: sub-committee for the development of benefit package and 
service delivery; UHC: Universal Health Coverage; WTP: willingness to pay.
Declarations
Authors’ contributions
All authors contributed to conceptualizing and writing this manuscript. All 
authors read and approved the final manuscript.
Author details
1 Patient Centred Research, Evidera, London, UK. 2 ScHARR, University of Shef-
field, Sheffield, UK. 3 Faculty of Pharmacy, Mahidol University, Bangkok, 
Thailand. 4 School of Public Health, Imperial College, London, UK. 5 Center 
for Global Development, London, UK. 
Acknowledgements
The authors would like to thank the team at the Harvard T.H. Chan School of 
Public Health who organized the workshop during which the ideas in this 
manuscript were first shared and discussed.
Competing interests
The authors declare that they have no competing interests.
Availability of data and materials
Not applicable.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Not applicable.
Publication funding
The publication costs for this article were funded by Mark O’Friel, the Brinson 
Foundation, and the Payne Family Foundation.
About this supplement
This article has been published as part of Cost Effectiveness and Resource 
Allocation Volume 16 Supplement 1, 2018: Priority Setting in Global Health. 
The full contents of the supplement are available online at https ://resou rce-
alloc ation .biome dcent ral.com/artic les/suppl ement s/volum e-16-suppl ement 
-1.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
Published: 9 November 2018
Page 68 of 98Marsh et al. Cost Eff Resour Alloc 2018, 16(Suppl 1):43
References
 1. National Institute for Health and Care Excellence (NICE). Guide to the 
methods of technology appraisal 2013. Process and methods [PMG9] 
2013. https ://www.nice.org.uk/proce ss/pmg9/chapt er/forew ord. 
Accessed July 2017.
 2. Baltussen R, Niessen L. Priority setting of health interventions: the need 
for multi-criteria decision analysis. Cost Eff Resour Alloc. 2006;4:14.
 3. Marsh K, Lanitis T, Neasham D, Orfanos P, Caro J. Assessing the value of 
healthcare interventions using multi-criteria decision analysis: a review of 
the literature. Pharmacoeconomics. 2014;32:345–65.
 4. Chalkidou K, Marten R, Cutler D, et al. Health technology assessment in 
universal health coverage. Lancet. 2013;382:e48–9.
 5. Oliver K, Innvar S, Lorenc T, Woodman J, Thomas J. A systematic review of 
barriers to and facilitators of the use of evidence by policymakers. BMC 
Health Serv Res. 2014;14:2.
 6. Baltussen R. Question is not whether but how to use MCDA. Value and 
Outcomes Spotlight; 2015.
 7. Mühlbacher A, Bridges J, Bethge S, et al. Choice-based conjoint analy-
sis—pilot project to identify, weight, and prioritize multiple attributes in 
the indication “hepatitis C”. IQWiG Report; 2013.
 8. Radaelli G, Lettieri E, Masella C, et al. Implementation of EUnetHTA core 
Model(R) in Lombardia: the VTS framework. Int J Technol Assess Health 
Care. 2014;30:105–12.
 9. Bae EY, Hong JM, Kwon HY, et al. Eight-year experience of using HTA in 
drug reimbursement: South Korea. Health Policy. 2016;120:612–20.
 10. Endrei D, Molics B, Agoston I. Multicriteria decision analysis in the reim-
bursement of new medical technologies: real-world experiences from 
Hungary. Value Health. 2014;17:487–9.
 11. National Institute for Health and Care Excellence (NICE). Interim process 
and methods of the highly specialised technologies programme 2013. 
https ://www.nice.org.uk/Media /Defau lt/About /what-we-do/NICE-guida 
nce/NICE-highl y-speci alise d-techn ologi es-guida nce/Highl y-Speci alise 
d-Techn ologi es-Inter im-metho ds-and-proce ss-state ments .pdf. Accessed 
July 2017.
 12. Adunlin G, Diaby V, Xiao H. Application of multicriteria decision analysis in 
health care: a systematic review and bibliometric analysis. Health Expect. 
2015;18:1894–905.
 13. Ramli A, Aljunid SM, Sulong S, Md Yusof FA. National drug formulary 
review of statin therapeutic group using the multiattribute scoring tool. 
Ther Clin Risk Manag. 2013;9:491–504.
 14. Diaby V, Lachaine J. An application of a proposed framework for formu-
lary listing in low-income countries: the case of Cote d’Ivoire. Appl Health 
Econ Health Policy. 2011;9:389–402.
 15. Nobre FF, Trotta LT, Gomes LF. Multi-criteria decision making—an 
approach to setting priorities in health care. Stat Med. 1999;18:3345–54.
 16. Youngkong S, Baltussen R, Tantivess S, Mohara A, Teerawattananon Y. 
Multicriteria decision analysis for including health interventions in the 
universal health coverage benefit package in Thailand. Value Health. 
2012;15:961–70.
 17. Youngkong S, Teerawattananon Y, Tantivess S, Baltussen R. Multi-criteria 
decision analysis for setting priorities on HIV/AIDS interventions in Thai-
land. Health Res Policy Syst. 2012;10:6.
 18. Jehu-Appiah C, Baltussen R, Acquah C, et al. Balancing equity and 
efficiency in health priorities in Ghana: the use of multicriteria decision 
analysis. Value Health. 2008;11:1081–7.
 19. Baltussen R, Stolk E, Chisholm D, Aikins M. Towards a multi-criteria 
approach for priority setting: an application to Ghana. Health Econ. 
2006;15:689–96.
 20. Baltussen R, ten Asbroek AH, Koolman X, et al. Priority setting using multi-
ple criteria: should a lung health programme be implemented in Nepal? 
Health Policy Plan. 2007;22:178–85.
 21. Holdsworth M, El Ati J, Bour A, et al. Developing national obesity policy in 
middle-income countries: a case study from North Africa. Health Policy 
Plan. 2013;28:858–70.
 22. Miot J, Wagner M, Khoury H, Rindress D, Goetghebeur MM. Field testing 
of a multicriteria decision analysis (MCDA) framework for coverage of a 
screening test for cervical cancer in South Africa. Cost Eff Resour Alloc. 
2012;10:2.
 23. Mohara A, Youngkong S, Velasco RP, et al. Using health technology 
assessment for informing coverage decisions in Thailand. J Comp Eff Res. 
2012;1:137–46.
 24. Marsh K, IJzerman M, Thokala P, et al. Multiple criteria decision analysis 
for health care decision making-emerging good practices: report 2 of 
the ISPOR MCDA emerging good practices task force. Value Health. 
2016;19:125–37.
 25. Dodgson J, Spackman M, Pearman A, Phillips L. Multi-criteria analysis: a 
manual. 2009. http://eprin ts.lse.ac.uk/12761 /1/Multi -crite ria_Analy sis.pdf. 
Accessed July 2017.
 26. Baltussen R. MCDA. Do not provide a mathematical solution to what 
really is an ethical problem. In: Priority Setting in global health sympo-
sium Oct 5–6, 2016. Boston: Harvard T.H. Chan School of Public Health; 
2016.
 27. Thokala P, Devlin N, Marsh K, et al. Multiple criteria decision analysis for 
health care decision making—an introduction: report 1 of the ISPOR 
MCDA emerging good practices task force. Value Health. 2016;19:1–13.
 28. Morton A. Treacle and smallpox: two tests for multicriteria decision analy-
sis models in health technology assessment. Value Health. 2017;20:512–5.
 29. Tromp N, Mikkelsen E, Viergever R, Baltussen R. Embedding MCDA in 
priority-setting policy processes: experiences from low- and middle-
income countries. In: Marsh K, Goetghebeur M, Thokala P, Baltussen R, 
editors. Multi-criteria decision analysis to support healthcare decisions. 
New York: Springer International Publishing; 2017.
 30. Thokala P, Ochalek J, Leech AA, Tong T. Cost-effectiveness thresholds: the 
past, the present and the future. Pharmacoeconomics. 2018;36:509–22.
 31. Raftery J. NICE: faster access to modern treatments? Analysis of guidance 
on health technologies. BMJ. 2001;323:1300–3.
 32. Claxton K, Martin S, Soares M, et al. Methods for the estimation of the 
NICE cost effectiveness threshold. CHE research paper 81; 2013. https ://
www.york.ac.uk/media /che/docum ents/paper s/resea rchpa pers/CHERP 
81_metho ds_estim ation _NICE_coste ffect ivene ss_thres hold_(Nov20 13).
pdf. Accessed July 2017.
 33. Barnsley P, Towse A, Karlsberg Schaffer S, Sussex J. Critique of CHE 
research paper 81: methods for the estimation of the NICE cost effective-
ness threshold. London: Office of Health Economics; 2013.
 34. Woods B, Revill P, Sculpher M, Claxton K. Determining value from health-
care spending: the role of cost-effectiveness thresholds; 2015. http://
www.idsih ealth .org/knowl edge_base/cost-effec tiven ess-thres holds /. 
Accessed Mar 2018.
 35. Bertram MY, Lauer JA, De Joncheere K, et al. Cost-effectiveness thresh-
olds: pros and cons. Bull World Health Organ. 2016;94:925–30.
 36. Airoldi M, Morton A, Smith J, Bevan G. Healthcare prioritisation at the 
local level: a socio-technical approach. Priority setting for population 
health, working paper series. London School of Economics and Political 
Science. Working paper no. 7; 2011.
 37. Wilson EC, Peacock SJ, Ruta D. Priority setting in practice: what is the best 
way to compare costs and benefits? Health Econ. 2009;18:467–78.
 38. Caro J, editor. The use of MCDA in Colombian HTA. HTAi: Tokyo; 2016.
 39. Personal communication with Aurelio Mejia Mejia, senior economist IETS.
 40. Tantivess S, Teerawattananon Y, Mills A. Strengthening cost-effectiveness 
analysis in Thailand through the establishment of the health inter-
vention and technology assessment program. Pharmacoeconomics. 
2009;27:931–45.
 41. Asia Pacific Observatory on Health Systems and Policies. Policy brief: con-
ducive factors to HTA development in Asia; 2013. http://www.wpro.who.
int/asia_pacifi c_obser vator y/resou rces/polic y_brief s/hta/en/. Accessed 
Mar 2018.
 42. Disease Control Priorities. Economic evaluation for health. http://dcp-3.
org/. Accessed Apr 2018.
 43. World Health Organization (WHO). CHOosing Interventions that are Cost 
Effective (WHO-CHOICE). WHO CHOICE Tools. http://www.who.int/choic 
e/toolk it/en/. Accessed Apr 2018.
 44. World Health Organization (WHO). Cost effectiveness and strategic 
planning (WHO-CHOICE). http://www.who.int/choic e/en/. Accessed Apr 
2018.
 45. Wong JQ, Haw NJ, Uy J, Bayani DB. Reflections on the use of the World 
Health Organization’s (WHO) OneHealth Tool: implications for health 
planning in low and middle income countries (LMICs). F1000Res. 
2018;7:157.
 46. Groothuis-Oudshoorn CGM, Broekhuizen H, van Til J. Dealing with uncer-
tainty in the analysis and reporting of MCDA. In: Marsh K, Goetghebeur 
M, Thokala P, Baltussen R, editors. Multi-criteria decision analysis to sup-
port healthcare decisions. Cham: Springer; 2017.
Page 69 of 98Marsh et al. Cost Eff Resour Alloc 2018, 16(Suppl 1):43
•
 
fast, convenient online submission
 
•
  
thorough peer review by experienced researchers in your field
• 
 
rapid publication on acceptance
• 
 
support for research data, including large and complex data types
•
  
gold Open Access which fosters wider collaboration and increased citations 
 
maximum visibility for your research: over 100M website views per year •
  
At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
Ready to submit your research  ?  Choose BMC and benefit from: 
 47. Phillips LD. Chapter 19: decision conferencing; 2006. http://eprin ts.lse.
ac.uk/22712 /1/06085 .pdf. Accessed July 2017.
 48. Teerawattananon Y, Tantivess S, Yothasamut J, Kingkaew P, Chaisiri K. 
Historical development of health technology assessment in Thailand. Int 
J Technol Assess Health Care. 2009;25(Suppl 1):241–52.
 49. Culyer AJ, Podhisita C, Santatiwongchai B. A star in the East. A short 
history of HITAP; 2016. http://www.idsih ealth .org/wp-conte nt/uploa 
ds/2016/02/A-STAR-IN-THE-EAST_resiz e.pdf. Accessed July 2017.
 50. HTAsiaLink. http://www.htasi alink .org/. Accessed July 2017.
 51. Li R. Mahidol University and NICE commit to strengthening HTA capacity; 
2015. http://www.idsih ealth .org/blog/mahid ol-nice-commi t-to-stren 
gthen ing-hta-capac ity/. Accessed Mar 2017.
 52. iDSI. Scholarship opportunity for health policy and technology assess-
ment HePTA program; 2016. http://www.idsih ealth .org/blog/hepta -schol 
arshi p-mahid ol/hepta -flyer /. Accessed July 2017.
 53. Downey L. Institutionalizing HTA in India—a joint iDSI-DHR event; 2016. 
http://www.idsih ealth .org/blog/insti tutio naliz ing-hta-in-india -a-joint -idsi-
dhr-event /. Accessed Mar 2017.
 54. Chalkidou K. Launch of China health policy and technology assessment 
network under auspices of NHFPC; 2016. http://www.idsih ealth .org/
blog/launc h-of-china -healt h-polic y-and-techn ology -asses sment -netwo 
rk-under -auspi ces-of-natio nal-healt h-and-famil y-plann ing-commi ttee/. 
Accessed Mar 2017.
 55. Downey LE, Mehndiratta A, Grover A, et al. Institutionalising health 
technology assessment: establishing the medical technology assessment 
board in India. BMJ Glob Health. 2017;2:e000259.
 56. Teerawattananon Y, Tritasavit N, Suchonwanich N, Kingkaew P. The use of 
economic evaluation for guiding the pharmaceutical reimbursement list 
in Thailand. Z Evid Fortbild Qual Gesundhwes. 2014;108:397–404.
 57. Kanpirom K, Luz ACG, Chalkidou K, Teerawattananon Y. How should 
global fund use value-for-money information to sustain its investments in 
graduating countries? Int J Health Policy Manag. 2017;6:1–5.
 58. Farmer P. Who Lives and who dies. London Rev Books. 2015;37:17–20.
 59. Parkin D, Appleby J, Maynard A. Economics: the biggest fraud ever perpe-
trated on the world? Lancet. 2013;382:e11–5.
 60. GOV.UK. Performance agreement: UK and the Global Fund to fight aids, 
tuberculosis and malaria; 2016. https ://www.gov.uk/gover nment /publi 
catio ns/perfo rmanc e-agree ment-uk-and-the-globa l-fund-to-fight -aids-
tuber culos is-and-malar ia. Accessed July 2017.
 61. Chootipongchaivat S, Tritasavit N, Luz A, Teerawattananon Y, Tantivess S. 
Factors conducive to the development of health technology assessment 
in Asia: impacts and policy options, vol. 4. Manila: WHO Policy Brief; 2015.
